Global Oncology/Cancer Drugs Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class Type;

Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy.

By Indication;

Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn192615708 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Oncology/Cancer Drugs Market (USD Million), 2021 - 2031

In the year 2024, the Global Oncology/Cancer Drugs Market was valued at USD 180,948.28 million. The size of this market is expected to increase to USD 300,202.09 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.5%.

The global oncology/cancer drugs market stands at the forefront of medical innovation and therapeutic advancements, driven by a pressing need to combat one of the most challenging health crises of our time. With cancer incidence rates on the rise worldwide, the demand for effective treatments has intensified, propelling pharmaceutical companies and researchers into a relentless pursuit of novel therapies. This dynamic market encompasses a diverse array of drug classes, from traditional chemotherapeutics to cutting-edge targeted therapies and immunotherapies, each offering unique promises and challenges in the battle against cancer.

Against the backdrop of increasing cancer prevalence and evolving treatment paradigms, the global oncology/cancer drugs market is characterized by a landscape defined by rapid scientific progress and intense competition. Pharmaceutical giants, biotechnology firms, and academic institutions are engaged in a relentless quest for innovation, driving the development of groundbreaking therapies that target specific molecular pathways implicated in various cancer types. Moreover, the market is witnessing a shift towards personalized medicine, with a growing emphasis on precision oncology approaches tailored to individual patient profiles, fostering hope for improved outcomes and reduced treatment-related toxicities.

However, amidst the remarkable strides in oncology drug development, challenges abound, ranging from regulatory hurdles and pricing pressures to emerging resistance mechanisms and the complexities of translating preclinical discoveries into clinically meaningful outcomes. Moreover, the unequal access to cancer care and disparities in healthcare infrastructure pose significant barriers to achieving equitable outcomes globally. Nonetheless, with collaborative efforts across sectors and a steadfast commitment to innovation, the global oncology/cancer drugs market is poised to continue its transformative journey, offering renewed hope to millions of patients affected by this relentless disease.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class Type
    2. Market Snapshot, By Indication
    3. Market Snapshot, By Region
  4. Global Oncology/Cancer Drugs Market Dynamics
    1. Drivers, Restraints and Opportunitiess
      1. Drivers
        1. Rising Cancer Incidence
        2. Increasing Healthcare Spending
        3. Growing Aging Population
      2. Restraints
        1. High Treatment Costs
        2. Limited Access to Care
        3. Drug Resistance
        4. Side Effects
      3. Opportunities
        1. Targeted Therapies Expansion
        2. Immunotherapy Innovations
        3. Precision Oncology Adoption
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Oncology/Cancer Drugs Market, By Drug Class Type, 2021 - 2031 (USD Million)
      1. Chemotherapy
      2. Targeted Therapy
      3. Immunotherapy (Biologic Therapy)
      4. Hormonal Therapy
    2. Global Oncology/Cancer Drugs Market, By Indication, 2021 - 2031 (USD Million)
      1. Lung Cancer
      2. Stomach Cancer
      3. Colorectal Cancer
      4. Breast Cancer
      5. Prostate Cancer
      6. Liver Cancer
      7. Esophagus Cancer
      8. Cervical Cancer
      9. Kidney Cancer
      10. Bladder Cancer
      11. Others
    3. Global Oncology/Cancer Drugs Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AbbVie Inc.
      2. Astellas Pharma Inc.
      3. AstraZeneca PLC
      4. Bristol-Myers Squibb Company
      5. Celgene Corporation
      6. F. HOFFMANN-LA ROCHE LTD.
      7. JOHNSON & JOHNSON
      8. Merck & Co., Inc.
      9. Novartis AG
      10. Pfizer Inc.
  7. Analyst Views
  8. Future Outlook of the Market